Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Memantine (Primary)
- Indications Parkinson's disease
- Focus Biomarker; Pharmacodynamics
- 31 Oct 2006 New trial record.